| 1 |
32743932 | Association of erythropoietin resistance and fibroblast growth factor 23 in dialysis patients: Results from the Japanese Dialysis Outcomes and Practice Patterns Study. | 2021 Jan |
1 |
| 2 |
29514156 | Cinacalcet for Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: A Meta-Analysis of Randomized Controlled Trials. | 2018 |
1 |
| 3 |
30379826 | Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study. | 2018 |
1 |
| 4 |
28336829 | [The effect of oral calcimimetics on cardiovascular events.] | 2017 |
1 |
| 5 |
26319799 | Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures. | 2016 Apr |
1 |
| 6 |
25154517 | Changes in bone mineral metabolism parameters, including FGF23, after discontinuing cinacalcet at kidney transplantation. | 2015 May |
2 |
| 7 |
25873267 | Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. | 2015 Jun 5 |
7 |
| 8 |
26059012 | Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. | 2015 Jul 7 |
3 |
| 9 |
24111496 | Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism. | 2014 Apr |
3 |
| 10 |
24500308 | Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. | 2014 Apr |
1 |
| 11 |
24975224 | Oral phosphorus supplementation secondarily increases circulating fibroblast growth factor 23 levels at least partially via stimulation of parathyroid hormone secretion. | 2014 |
1 |
| 12 |
23705925 | Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study. | 2013 May 25 |
5 |
| 13 |
21730210 | Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. | 2012 Feb |
3 |
| 14 |
21874285 | Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism. | 2012 Oct |
3 |
| 15 |
22606047 | Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease. | 2012 |
1 |
| 16 |
19965548 | Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. | 2010 Jan |
3 |
| 17 |
20583336 | Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease. | 2010 Jul |
1 |
| 18 |
20688626 | Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review. | 2010 Jul-Sep |
1 |
| 19 |
18256372 | Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. | 2008 May |
1 |
| 20 |
18950915 | Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism. | 2008 Dec |
2 |
| 21 |
17352646 | Cinacalcet in the management of tumor-induced osteomalacia. | 2007 Jun |
3 |